# US 10,500,217 B2 · Vitamin D3, heat shock proteins, and glutathione for the treatment of chronic inflammation and chronic diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,500,217 B2
- Document ID: US10500217B2
- Status: Granted
- Kind: B2
- Application number: 15/967,516
- Filed: 2018-04-30
- Published: 2019-10-31
- Granted: 2019-12-10
- Earliest claimed: 2018-04-30
- Assignees: Leslie Ray Matthews, M.D., LLC
- Applicants: Leslie Ray Matthews; Alexzander Asea
- Inventors: Leslie Ray Matthews; Alexzander Asea
- Web page: https://patentgrep.com/patent/US10500217B2

## CPC

- A61K 31/593: 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 9/4825: {Proteins, e.g. gelatin (gelatin capsule shells with substantial amounts of other macromolecular substances A61K9/4816)}
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 11/08: Bronchodilators
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 38/063: {Glutathione}
- A61K 2039/6043: {Heat shock proteins}
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure is directed to co-administration of high dose Vitamin D3, heat shock proteins, glutathione, and kits provided for co-administration of these compositions, for the treatment of patients with chronic inflammation and chronic diseases.

## Claims

### Claim 1

A method of treating traumatic brain injury in a patient comprising co-administering to the patient a first composition consisting essentially of Vitamin D3 and a second composition consisting essentially of heat shock proteins.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the first composition consists essentially of about 1,000 IU to about 150,000 IU of Vitamin D3.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the second composition consists essentially of about 100 mg to about 1,000 mg of heat shock proteins.

### Claim 4 (depends on 1)

The method according to claim 1, wherein:
(i) about 150,000 IU of Vitamin D3 is administered to the patient for about five days;
(ii) about 50,000 IU of Vitamin D3 is administered to the patient weekly beginning on the 6th day of treatment; and
(iii) about 1,000 mg of heat shock proteins is administered to the patient daily beginning on the 6t day of treatment.

### Claim 5 (depends on 1)

The method according to claim 1, wherein:
(i) about 5,000 IU of Vitamin D3; and
(ii) about 500 mg of heat shock proteins
is administered to the patient daily for about two weeks.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the heat shock proteins is selected from the group consisting of twenty-seven kilo Dalton heat shock protein (Hsp27); sixty kilo Dalton heat shock protein (Hsp60); sixty-five kilo Dalton heat shock protein (Hsp65); seventy kilo Dalton heat shock protein (Hsp70); seventy-two kilo Dalton heat shock protein (Hsp72); and ninety kilo Dalton heat shock protein (Hsp90).

### Claim 7 (depends on 1)

The method according to claim 1, wherein the method of treating further comprises administering to the patient a composition comprising glutathione.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the composition consists essentially of about 500 mg to about 1,000 mg of glutathione.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the dosage form is an oral dosage form.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the dosage form is a tablet, capsule or gel capsule.